MedTrace Logo

Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes

NCT06854861 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-13

No results posted yet for this study

Summary

We will investigate if Lyumjev premixed with nanogram amounts of glucagon speed up the absorption of insulin and the effect on whole body glucose consumption compared to native lyumjev in patients with type 1 diabetes. To do that we will perform euglycemic clamps investigations in patients meetinng fasting in the morning on two separate days.Frequent samples for glucose and insulin measuremenst will be drawn and the day with lyumjev only will be compared to the day with premixed Lyumjev.

Conditions

Interventions

DRUG

Lyumjev 100 UNT/ML Injectable Solution

0.1 unit insulin Lyumjev /kg body weight is injected subcutaneously

DRUG

Premixed Lyumjev

A solution of 5 ng glucagon /Unit Lyumjev is injcetd subcutaneously. 0.1 unit insulin / kg body weight is used.

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Sven M Carlsen, MD PhD · St. Olav/NTNU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2025-11-30
Completion
2025-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06854861 on ClinicalTrials.gov